logo
Plus   Neg
Share
Email
Comment

Merck Gets Positive CHMP Opinion For Prevymis In EU - Quick Facts

Merck & Co. Inc. (MRK), known as MSD outside the U.S. and Canada, said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted a positive opinion recommending approval of Prevymis (letermovir) for prophylaxis of cytomegalovirus or CMV reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).

The CHMP positive opinion will be considered by the European Commission. If the CHMP opinion is affirmed, the EC will grant a centralized marketing authorization with unified labeling that is valid in the 28 countries of the European Union or EU, as well as European Economic Area members, Iceland, Liechtenstein and Norway.

Merck said it expects that the European Commission decision will be adopted within approximately two months.

In the pivotal Phase 3 clinical trial evaluating letermovir, significantly fewer patients in the Prevymis arm compared to the placebo arm developed clinically significant CMV infection, discontinued treatment or had missing data through Week 24 post-HSCT, the primary efficacy endpoint.

Prevymis was approved by the U.S. Food and Drug Administration or FDA on November 8. In the U.S., Prevymis is indicated for prophylaxis of cytomegalovirus infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant.

Merck also has filed letermovir for regulatory approval in other markets including Japan, where it is currently under review.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Bank of America Corp. (BAC) reported a profit for the fourth-quarter of 2017 that declined about 50 percent from last year, hurt by a charge of $2.9 billion or $0.27 per share, related to the Tax Cuts and Jobs Act. Retail giant Walmart Wednesday announced the launch of an opioid disposal solution, known as DisposeRx, which will help in its fight against opioid abuse and misuse. The free first-of-its kind solution will be available in all company pharmacies, making the retailer the first national pharmacy chain to do so. ASML Holding NV reported higher profit and sales in its fourth quarter with increased system sales, despite weak gross margin. Going ahead, the company projects continued solid growth of sales and profitability in 2018. Separately, ASML said its Supervisory Board intends to appoint Roger Dassen as Executive Vice President and Chief Financial Officer, effective June 1.
comments powered by Disqus
Follow RTT